Stocks To Buy Now

Blog


Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Continues Showcasing Proprietary Research at Cannabis Investment Conferences

  • Proprietary Lexaria technology improves delivery of bioactive compounds in a variety of products, including cannabis-based gourmet foods
  • Market predictions for the legal marijuana industry forecast $50 billion in sales by 2026
  • 19 patent applications filed and pending in more than 40 countries

Following a successful showing at the inaugural Institutional Capital & Cannabis Conference (IC3) in California earlier this month, Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) CEO Chris Bunka expects the company to be noticed by investors. Bunka’s presentation of the company’s latest technology slated to benefit the cannabis industry includes the world’s first clinical study on human volunteers of cannabidiol (CBD) within Lexaria’s TurboCBD™ product.

The study, which aims to evaluate the effects of TurboCBD™ on both cardiovascular health and cognitive function, will have a double-blind and placebo controlled cross-over design measuring effects after a single dose, as well as seven days of daily dosing, in 24 volunteers (http://dtn.fm/2LsAq).

“Results will advance Lexaria’s ability to custom design products that increase the leading performance our technology already offers to customers,” Bunka said in a press release outlining the project.

While Hurricane Irma has postponed Bunka’s next mainstream presentation, slated for the now on-hold Institutional Capital & Cannabis Conference in Miami Beach, Florida, Lexaria continues its drive to showcase the benefits of the company’s unique patented delivery technology (http://dtn.fm/7dVat).

Lexaria researchers work to solve a critical problem facing the cannabis industry – the fact that most of the CBD and tetrahydrocannabinol (THC) that people consume, through any method, is literally flushed away in the proverbial toilet. To that end, Lexaria has focused on discovering new technologies that can more efficiently deliver cannabinoids to the bloodstream, where they can have their desired effect.

Lexaria’s patented DehydraTECH™ technology solves this problem by delivering cannabinoids in an oral form that masks any undesirable taste but increases bioabsorption, speed of effectiveness and potency. This method of delivery is a more viable and healthier method than smoking or vaping cannabis, a route that non-users and medical providers frown upon due to documented health concerns.

Marijuana is now legal in some form in 29 states and Canada. In fact, the Canadian government is expected to legalize adult use of cannabis in 2018, and there are growing movements in the U.S. to legalize cannabis nationwide, as well. Industry experts predict that U.S. retail sales alone could reach $50 billion by 2026 (http://dtn.fm/9elrN).

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

Latest From Twitter

Follow us: @Buy_Stocks_Now

From Our Blog

Moxian, Inc. (NASDAQ: MOXC) Targets Four Key Cities in China, Eyes Revenue Growth

November 21, 2017

Shanghai, Beijing, Shenzhen and Guangzhou are metropolitan markets targeted for MOXC’s growth China’s population is the world’s largest; goal is to convert its Moxian+ Business and Moxian+ User app platforms from free to paid Report: 1.39 billion mobile phone users registered in China, makes it largest globally Moxian, Inc. (NASDAQ: MOXC) is targeting four key […]

Rotate your device 90° to view site.